10x Genomics Dirección

Dirección controles de criterios 3/4

El CEO de 10x Genomics es Serge Saxonov , nombrado en Jul 2012, tiene una permanencia de 12.33 años. compensación anual total es $8.29M, compuesta por 6.6% salario y 93.4% primas, incluidas acciones y opciones de la empresa. posee directamente un 3.32% de las acciones de la empresa, por valor de €57.17M. La antigüedad media del equipo directivo y de la junta directiva es de 2.8 años y 5.4 años, respectivamente.

Información clave

Serge Saxonov

Chief Executive Officer (CEO)

US$8.3m

Compensación total

Porcentaje del salario del CEO	6.6%
Permanencia del CEO	12.3yrs
Participación del CEO	3.3%
Permanencia media de la dirección	2.8yrs
Promedio de permanencia en la Junta Directiva	5.4yrs

Actualizaciones recientes de la dirección

Recent updates

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Serge Saxonov en comparación con los beneficios de 10x Genomics?
Fecha	Compensación total	Salario	Ingresos de la empresa
Sep 30 2024	n/a	n/a	-US$183m
Jun 30 2024	n/a	n/a	-US$240m
Mar 31 2024	n/a	n/a	-US$264m
Dec 31 2023	US$8m	US$545k	-US$255m
Sep 30 2023	n/a	n/a	-US$223m
Jun 30 2023	n/a	n/a	-US$172m
Mar 31 2023	n/a	n/a	-US$174m
Dec 31 2022	US$19m	US$504k	-US$166m
Sep 30 2022	n/a	n/a	-US$167m
Jun 30 2022	n/a	n/a	-US$142m
Mar 31 2022	n/a	n/a	-US$89m
Dec 31 2021	US$12m	US$430k	-US$58m
Sep 30 2021	n/a	n/a	-US$455m
Jun 30 2021	n/a	n/a	-US$504m
Mar 31 2021	n/a	n/a	-US$533m
Dec 31 2020	US$11m	US$400k	-US$543m
Sep 30 2020	n/a	n/a	-US$134m
Jun 30 2020	n/a	n/a	-US$78m
Mar 31 2020	n/a	n/a	-US$49m
Dec 31 2019	US$2m	US$394k	-US$31m
Sep 30 2019	n/a	n/a	-US$100m
Jun 30 2019	n/a	n/a	-US$105m
Mar 31 2019	n/a	n/a	-US$105m
Dec 31 2018	US$1m	US$366k	-US$112m

Compensación vs. Mercado: La compensación total de Serge($USD8.29M) está por encima de la media de empresas de tamaño similar en el mercado German ($USD1.65M).

Compensación vs. Ingresos: La compensación de Serge ha sido consistente con los resultados de la empresa en el último año.

CEO

Serge Saxonov (47 yo)

12.3yrs

Permanencia

US$8,286,050

Compensación

Dr. Serge Saxonov, Ph D, Co-Founded 10X Genomics, Inc. and has been its Chief Executive Officer and Director since July 2012. Prior to 10x Genomics, Dr. Saxonov was Vice President of Applications at Quanta...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Serge Saxonov	Co-Founder	12.3yrs	US$8.29m	3.32% € 57.2m
Benjamin Hindson	Co-Founder	12.3yrs	US$4.43m	2.68% € 46.0m
Eric Whitaker	Chief Legal Officer	7.3yrs	US$3.88m	0.12% € 2.0m
Adam Taich	CFO, Treasurer	less than a year	sin datos	sin datos
Jim Goodrich	Chief of Global Operations	less than a year	sin datos	sin datos
Michael Schnall-Levin	Founding Scientist & CTO	2.8yrs	sin datos	sin datos
Alexander Wong	Chief Information Officer	less than a year	sin datos	sin datos
Cassie Corneau	Manager of Investor Relations & Strategic Finance	no data	sin datos	sin datos
Rebecca Port	Chief People Officer	3.8yrs	sin datos	sin datos
Mennah Moustafa	Chief Commercial Officer	less than a year	sin datos	sin datos
Jens Durruthy	Associate Director of Product Management	no data	sin datos	sin datos

2.8yrs

Permanencia media

48.5yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de 1KJ se considera experimentado (2.8 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Serge Saxonov	Co-Founder	12.3yrs	US$8.29m	3.32% € 57.2m
Benjamin Hindson	Co-Founder	12.3yrs	US$4.43m	2.68% € 46.0m
Kimberly Popovits	Independent Director	4.7yrs	US$338.71k	0.0038% € 65.5k
John Stuelpnagel	Independent Chairman	11.3yrs	US$403.59k	2.02% € 34.7m
Shehnaaz Suliman	Independent Director	5.3yrs	US$336.39k	0.0038% € 65.5k
Alan Mateo	Director	less than a year	sin datos	sin datos
Sridhar Kosaraju	Independent Director	5.6yrs	US$346.39k	0.029% € 503.6k
Sarah Polonius-Teichmann	Director	less than a year	sin datos	sin datos

5.4yrs

Permanencia media

52yo

Promedio de edad

Junta con experiencia: La junta directiva de 1KJ se considera experimentada (5.4 años de antigüedad promedio).

10x Genomics Dirección

Dirección controles de criterios 3/4

Información clave

Actualizaciones recientes de la dirección

10x Genomics, Inc., Annual General Meeting, Jun 11, 2024

James Wilbur to Depart from 10X Genomics, Inc. as Chief Commercial Officer, Effective from February 1, 2024

Chief Commercial Officer recently sold €566k worth of stock

Chief Commercial Officer recently sold €409k worth of stock

10X Genomics, Inc. Announces Board Changes

Independent Chairman recently sold €512k worth of stock

Recent updates

Third quarter 2024 earnings released: US$0.30 loss per share (vs US$0.79 loss in 3Q 2023)

10x Genomics, Inc. Announces Launch of Two New Chromium Products Intends to Democratize Access to Single Cell Analysis - GEM-X Flex and GEM-X Universal Multiplex

10x Genomics, Inc. to Report Q3, 2024 Results on Oct 29, 2024

New major risk - Share price stability

10x Genomics, Inc. Announces Launch of Chromium Xo, A New Addition to Its Fleet of Chromium Single Cell Instruments

New major risk - Share price stability

New minor risk - Shareholder dilution

Second quarter 2024 earnings released

10X Genomics, Inc. Revises Earnings Guidance for Full Year 2024

10x Genomics, Inc. to Report Q2, 2024 Results on Aug 08, 2024

10x Genomics, Inc. Launches 5,000-Plex Gene Panel for Xenium

10x Genomics, Inc. Reaffirms Revenue Guidance for the Year 2024

First quarter 2024 earnings released: US$0.50 loss per share (vs US$0.44 loss in 1Q 2023)

10x Genomics, Inc., Annual General Meeting, Jun 11, 2024

10x Genomics, Inc. to Report Q1, 2024 Results on Apr 30, 2024

10x Genomics, Inc. Commercially Launches Visium HD Spatial Gene Expression Assay

10X Genomics Expands Xenium Menu with Multi-Modal Cell Segmentation Kit and Immuno-Oncology Gene Panel

10x Genomics, Inc. Begins Commercial Shipments of Chromium GEM-X Products

Full year 2023 earnings released: US$2.18 loss per share (vs US$1.46 loss in FY 2022)

10X Genomics, Inc. Provides Revenue Guidance for the Full Year 2024

10x Genomics, Inc. Expands Leadership in Single Cell Analysis with Launch of GEM-X Technology

10x Genomics, Inc. to Report Q4, 2023 Results on Feb 15, 2024

James Wilbur to Depart from 10X Genomics, Inc. as Chief Commercial Officer, Effective from February 1, 2024

New minor risk - Profitability

Forecast to breakeven in 2026

Chief Commercial Officer recently sold €566k worth of stock

10X Genomics, Inc. Raises Revenue Guidance for Full Year 2023

Third quarter 2023 earnings released: US$0.79 loss per share (vs US$0.37 loss in 3Q 2022)

10X Genomics, Inc. Announces Study Fueled by Xenium Analysis Sheds Light on Resistance Mechanisms in Model of Lethal Pediatric Brain Tumors

10x Genomics, Inc. to Report Q3, 2023 Results on Nov 02, 2023

10x Genomics, Inc. Expands Gene Expression Flex Offering with New High-Throughput Multiomic Profiling Kit

10X Genomics, Inc. Announces Use of Its Technologies in A Study Published in the Journal of Clinical Investment

Chief Commercial Officer recently sold €409k worth of stock

10x Genomics, Inc. Raises Revenue Guidance for the Full Year 2023

Second quarter 2023 earnings released: US$0.54 loss per share (vs US$0.57 loss in 2Q 2022)

Forecast to breakeven in 2025

Forecast to breakeven in 2025

10X Genomics, Inc. Announces Board Changes

New minor risk - Share price stability

10x Genomics, Inc. to Report Q2, 2023 Results on Aug 03, 2023

Vizgen, Inc. Provides Update on Litigation

10x Genomics, Inc.(NasdaqGS:TXG) dropped from Russell Small Cap Comp Value Index

Independent Chairman recently sold €512k worth of stock

Co-Founder recently sold €133k worth of stock

10X Genomics, Inc. Revises Revenue Guidance for the Full Year 2023

First quarter 2023 earnings released: US$0.44 loss per share (vs US$0.38 loss in 1Q 2022)

Forecast to breakeven in 2025

Now 20% undervalued

Forecast to breakeven in 2025

Co-Founder recently sold €87k worth of stock

Full year 2022 earnings released: US$1.46 loss per share (vs US$0.53 loss in FY 2021)

10x Genomics, Inc. Provides Revenue Guidance for the Full Year 2023

10x Genomics, Inc. to Report Q4, 2022 Results on Feb 15, 2023

10x Genomics, Inc. Launches Xenium Platform for In Situ Analysis

Co-Founder recently sold €89k worth of stock

Insufficient new directors

10X Genomics, Inc. Announces Commercial Availability of BEAM

Third quarter 2022 earnings released: US$0.37 loss per share (vs US$0.15 loss in 3Q 2021)

10X Genomics, Inc. Provides Revenue Guidance for Full Year 2022

10x Genomics, Inc. to Report Q3, 2022 Results on Nov 02, 2022

Insufficient new directors

Co-Founder recently sold €96k worth of stock

No longer forecast to breakeven

10X Genomics, Inc. Provides Earnings Guidance for the Third Quarter of 2022 and Full Year 2022

Second quarter 2022 earnings released: US$0.57 loss per share (vs US$0.10 loss in 2Q 2021)

Forecast breakeven date moved forward to 2023

10x Genomics, Inc. to Report Q2, 2022 Results on Aug 08, 2022

10x Genomics Inc. Advances Leadership and Innovation in Single Cell and Spatial Technologies At 2022 AGBT General Meeting

Co-Founder recently sold €121k worth of stock